Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Pentazocine

Targets (3)Biointeractions (3)

Identification

Name

Pentazocine

Accession Number

DB00652 (APRD01173)

Type

Small Molecule

Groups

Approved, Vet approved

Description

The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)

Structure

Similar Structures

Synonyms

Pentazocin
Pentazocina
Pentazocine
Pentazocinum

External IDs

CS 350 / NIH 7958 / Win 20228

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Pentazocine Hydrochloride	A36BXO4PPX	64024-15-3	OQGYMIIFOSJQSF-DTOXXUQYSA-N
Pentazocine Lactate	1P2XIB510O	17146-95-1	QNLDTXPVZPRSAM-DTOXXUQYSA-N

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Talwin	Injection, solution	30 mg/mL	Intramuscular; Intravenous; Subcutaneous	General Injectables & Vaccines	2010-08-01	2017-01-25
Talwin	Injection, solution	30 mg/mL	Intramuscular; Intravenous; Subcutaneous	Hospira, Inc.	2005-11-18	2018-04-10
Talwin	Injection, solution	30 mg/mL	Intramuscular; Intravenous; Subcutaneous	Hospira, Inc.	2010-10-12	2017-08-11
Talwin	Tablet	50 mg	Oral	Sanofi Aventis	1970-12-31	Not applicable
Talwin	Solution	30 mg	Intramuscular; Intravenous; Subcutaneous	Pfizer	2002-11-01	Not applicable
Talwin - Liq 30mg/ml	Liquid	30 mg	Intramuscular; Intravenous; Subcutaneous	Sanofi Synthelabo	1967-12-31	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Pentazocine and naloxone	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc	1997-01-21	2017-09-21
Pentazocine and Naloxone	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Golden State Medical Supply	2000-03-24	Not applicable
Pentazocine and naloxone	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Actavis Pharma Company	1997-01-21	Not applicable
Pentazocine and naloxone	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Keltman Pharmaceuticals Inc.	2009-07-21	Not applicable
Pentazocine and naloxone	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Pd Rx Pharmaceuticals, Inc.	1997-01-21	Not applicable
Pentazocine and naloxone	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	bryant ranch prepack	1997-01-21	Not applicable
Pentazocine HCl and Acetaminophen	Pentazocine Hydrochloride (25 mg/1) + Acetaminophen (650 mg/1)	Tablet	Oral	Rebel Distributors	2000-03-24	Not applicable
Pentazocine HCl and Naloxone HCl	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Stat Rx USA	1997-01-21	2018-02-08
Pentazocine Hydrochloride and Acetaminophen	Pentazocine Hydrochloride (25 mg/1) + Acetaminophen (650 mg/1)	Tablet	Oral	Gavis Pharmaceuticals, LLC.	2011-05-11	Not applicable
Pentazocine Hydrochloride and Naloxone Hydrochloride	Pentazocine Hydrochloride (50 mg/1) + Naloxone hydrochloride (.5 mg/1)	Tablet	Oral	Directrx	2014-01-01	Not applicable

International/Other Brands

Fortal (Sanofi-Aventis) / Fortral (Sanofi-Aventis) / Fortwin (Terapia) / Pangon (L.B.S.) / Pentagin (Daiichi Sankyo) / Sosegon (Sanofi-Aventis) / Stopain (Beximco) / Talwin PX (Sanofi-Aventis)

Categories

UNII

768DQ5A5AI

CAS number

359-83-1

Weight

Average: 285.4238
Monoisotopic: 285.209264491

Chemical Formula

C₁₉H₂₇NO

InChI Key

VOKSWYLNZZRQPF-GDIGMMSISA-N

InChI

InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1

IUPAC Name

(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-azatricyclo[7.3.1.0²,⁷]trideca-2,4,6-trien-4-ol

SMILES

C[[email protected]]1[[email protected]]2CC3=CC=C(O)C=C3[[email protected]]1(C)CCN2CC=C(C)C

Pharmacology

Indication

For the relief of moderate to severe pain.

Structured Indications

Pharmacodynamics

Pentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.

Mechanism of action

The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor.

Target	Actions	Organism
AMu-type opioid receptor	antagonist	Human
AKappa-type opioid receptor	agonist	Human
ASigma non-opioid intracellular receptor 1	agonist	Human

Absorption

Well absorbed from the gastro-intestinal tract.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic

Route of elimination

Not Available

Half life

2 to 3 hours

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Pentazocine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Pentazocine.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	2,5-Dimethoxy-4-ethylthioamphetamine may increase the analgesic activities of Pentazocine.	Experimental
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Pentazocine is combined with 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when Pentazocine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.	Experimental
Acepromazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Aceprometazine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Acetazolamide.	Approved, Vet Approved
Aclidinium	The risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Pentazocine is combined with Adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine.	Approved, Investigational
Alaproclate	Pentazocine may increase the serotonergic activities of Alaproclate.	Experimental
Alcuronium	The risk or severity of adverse effects can be increased when Alcuronium is combined with Pentazocine.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Alfaxalone.	Vet Approved
Alfentanil	Pentazocine may decrease the analgesic activities of Alfentanil.	Approved, Illicit
Alimemazine	Alimemazine may increase the hypotensive activities of Pentazocine.	Approved, Vet Approved
Allopregnanolone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Allopregnanolone.	Investigational
Alphacetylmethadol	Pentazocine may decrease the analgesic activities of Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	Pentazocine may decrease the analgesic activities of Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine.	Approved, Illicit, Investigational
Alvimopan	The risk or severity of adverse effects can be increased when Pentazocine is combined with Alvimopan.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amiloride.	Approved
Amisulpride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline.	Approved
Ammonium chloride	Ammonium chloride may increase the excretion rate of Pentazocine which could result in a lower serum level and potentially a reduction in efficacy.	Approved, Investigational, Vet Approved
Amobarbital	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amperozide.	Experimental
Amphetamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Amphetamine.	Approved, Illicit, Investigational
Anisotropine Methylbromide	The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pentazocine.	Approved
Aripiprazole	The risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Asenapine.	Approved
Atracurium	The risk or severity of adverse effects can be increased when Atracurium is combined with Pentazocine.	Approved, Experimental, Investigational
Atracurium besylate	The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.	Approved
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Pentazocine.	Approved, Vet Approved
Azaperone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Azaperone.	Investigational, Vet Approved
Azelastine	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azosemide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Azosemide.	Investigational
Baclofen	The risk or severity of adverse effects can be increased when Pentazocine is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.	Illicit
Benactyzine	The risk or severity of adverse effects can be increased when Benactyzine is combined with Pentazocine.	Withdrawn
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Bendroflumethiazide.	Approved
Benmoxin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Benmoxin.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Benperidol.	Approved, Investigational
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Pentazocine.	Approved
Benzocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Benzocaine.	Approved, Investigational
Benzphetamine	Benzphetamine may increase the analgesic activities of Pentazocine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Benzyl alcohol.	Approved
Bezitramide	Pentazocine may decrease the analgesic activities of Bezitramide.	Experimental, Illicit, Withdrawn
Biperiden	The risk or severity of adverse effects can be increased when Biperiden is combined with Pentazocine.	Approved, Investigational
BL-1020	BL-1020 may increase the hypotensive activities of Pentazocine.	Investigational
Bornaprine	The risk or severity of adverse effects can be increased when Bornaprine is combined with Pentazocine.	Experimental
Brexpiprazole	The risk or severity of adverse effects can be increased when Pentazocine is combined with Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved
Brofaromine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Brofaromine.	Experimental
Bromazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromazepam.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromisoval.	Experimental
Bromperidol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Brotizolam.	Approved, Investigational, Withdrawn
Bumetanide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Bupivacaine.	Approved, Investigational
Buprenorphine	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Pentazocine.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Pentazocine is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Pentazocine is combined with Butamben.	Approved, Withdrawn
Butethal	The risk or severity of adverse effects can be increased when Pentazocine is combined with Butethal.	Approved, Illicit
Butorphanol	Butorphanol may decrease the analgesic activities of Pentazocine.	Approved, Illicit, Vet Approved
Butylscopolamine	The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Pentazocine.	Approved, Investigational, Vet Approved
Canertinib	The risk or severity of adverse effects can be increased when Pentazocine is combined with Canertinib.	Investigational
Canrenoic acid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenoic acid.	Approved, Withdrawn
Canrenone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Canrenone.	Investigational
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Carbinoxamine.	Approved
Carfentanil	Pentazocine may decrease the analgesic activities of Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Caroxazone.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pentazocine.	Approved, Illicit, Investigational
Chlormezanone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlormezanone.	Approved, Investigational, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine.	Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorphenamine.	Approved
Chlorphenoxamine	The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Pentazocine.	Withdrawn
Chlorphentermine	Chlorphentermine may increase the analgesic activities of Pentazocine.	Illicit, Withdrawn
Chlorproethazine	Chlorproethazine may increase the hypotensive activities of Pentazocine.	Experimental
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pentazocine.	Approved, Investigational, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone.	Approved
Cicletanine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cicletanine.	Investigational
Cinchocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cinchocaine.	Approved, Vet Approved
Citalopram	Pentazocine may increase the serotonergic activities of Citalopram.	Approved
Clemastine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clemastine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clobazam.	Approved, Illicit
Clofenamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clofenamide.	Experimental
clomethiazole	The risk or severity of adverse effects can be increased when Pentazocine is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clomipramine.	Approved, Investigational, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clonidine.	Approved
Clopamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clopamide.	Experimental
Clopenthixol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clopenthixol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Pentazocine.	Approved, Illicit
Clorexolone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clorexolone.	Experimental
Clothiapine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Clothiapine.	Experimental
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Pentazocine.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cocaine.	Approved, Illicit
Codeine	Pentazocine may decrease the analgesic activities of Codeine.	Approved, Illicit
Conivaptan	The risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.	Approved, Investigational
Cyclizine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.	Approved
Cyclopenthiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclopenthiazide.	Experimental
Cyclopentolate	The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentazocine.	Approved
Cyclopropane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclopropane.	Experimental
Cyclothiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclothiazide.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Cyproheptadine.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.	Approved, Investigational
Dapiprazole	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dapiprazole.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dapoxetine is combined with Pentazocine.	Investigational
Darifenacin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine.	Approved, Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.	Approved, Investigational
Desloratadine	The risk or severity of adverse effects can be increased when Desloratadine is combined with Pentazocine.	Approved, Investigational
Desmopressin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.	Approved
Desvenlafaxine	Pentazocine may increase the serotonergic activities of Desvenlafaxine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Detomidine.	Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine.	Approved
Dexetimide	The risk or severity of adverse effects can be increased when Dexetimide is combined with Pentazocine.	Withdrawn
Dexmedetomidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	Dextroamphetamine may increase the analgesic activities of Pentazocine.	Approved, Illicit
Dextromoramide	Pentazocine may decrease the analgesic activities of Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	Pentazocine may decrease the analgesic activities of Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	Pentazocine may decrease the analgesic activities of Dezocine.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Diazepam.	Approved, Illicit, Investigational, Vet Approved
Dicyclomine	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.	Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Pentazocine is combined with Diethyl ether.	Experimental
Diethylpropion	Diethylpropion may increase the analgesic activities of Pentazocine.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	Pentazocine may decrease the analgesic activities of Dihydrocodeine.	Approved, Illicit
Dihydroetorphine	Pentazocine may decrease the analgesic activities of Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	Pentazocine may decrease the analgesic activities of Dihydromorphine.	Experimental, Illicit
Dimenhydrinate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Diphenhydramine.	Approved, Investigational
Diphenoxylate	Pentazocine may decrease the analgesic activities of Diphenoxylate.	Approved, Illicit
Dixyrazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dixyrazine.	Experimental
Doramectin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Doramectin.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.	Approved, Investigational
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved, Vet Approved
DPDPE	Pentazocine may decrease the analgesic activities of DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved, Vet Approved
Drospirenone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone.	Approved
Drotebanol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Drotebanol.	Experimental, Illicit
Duloxetine	Pentazocine may increase the serotonergic activities of Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.	Approved, Investigational
Efonidipine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Efonidipine.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Eltanolone.	Investigational
Eluxadoline	Pentazocine may increase the constipating activities of Eluxadoline.	Approved, Investigational
Emepronium	The risk or severity of adverse effects can be increased when Emepronium is combined with Pentazocine.	Experimental
Enflurane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Enflurane.	Approved, Investigational, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Entacapone.	Approved, Investigational
Epitizide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Epitizide.	Experimental
Eplerenone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Eplerenone.	Approved
Escitalopram	Pentazocine may increase the serotonergic activities of Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Estazolam.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine.	Approved, Investigational
Etacrynic acid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.	Approved, Investigational
Etanautine	The risk or severity of adverse effects can be increased when Etanautine is combined with Pentazocine.	Experimental
Ethanol	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethopropazine	The risk or severity of adverse effects can be increased when Ethopropazine is combined with Pentazocine.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethotoin.	Approved
Ethoxzolamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethoxzolamide.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	Pentazocine may decrease the analgesic activities of Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Etifoxine.	Investigational, Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Etomidate.	Approved
Etoperidone	Pentazocine may increase the serotonergic activities of Etoperidone.	Withdrawn
Etorphine	Pentazocine may decrease the analgesic activities of Etorphine.	Illicit, Vet Approved
Etybenzatropine	The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Pentazocine.	Experimental
Ezogabine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ezogabine.	Approved, Investigational
Felbamate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenquizone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fenquizone.	Experimental
Fentanyl	Pentazocine may decrease the analgesic activities of Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Pentazocine.	Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fexofenadine.	Approved, Investigational
Flibanserin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.	Approved, Investigational
Fluanisone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluanisone.	Experimental
Fludiazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	Pentazocine may increase the serotonergic activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Pentazocine.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam.	Approved, Illicit, Investigational
Fluspirilene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluspirilene.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fluvoxamine.	Approved, Investigational
Fosphenytoin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fosphenytoin.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Fospropofol.	Approved, Illicit, Investigational
Furazolidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Furazolidone.	Approved, Investigational, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Furosemide.	Approved, Vet Approved
Gabapentin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin Enacarbil.	Approved, Investigational
Gallamine	The risk or severity of adverse effects can be increased when Gallamine is combined with Pentazocine.	Experimental
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pentazocine.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit, Investigational
Gepefrine	Gepefrine may increase the analgesic activities of Pentazocine.	Experimental
Gepirone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Glutethimide.	Approved, Illicit
Glycopyrronium	The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Pentazocine.	Approved, Investigational, Vet Approved
Guanfacine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.	Approved
Halothane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.	Approved, Vet Approved
Harmaline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Harmaline.	Experimental
Heroin	Pentazocine may decrease the analgesic activities of Heroin.	Approved, Illicit, Investigational
Hexamethonium	The risk or severity of adverse effects can be increased when Hexamethonium is combined with Pentazocine.	Experimental
Hexobarbital	The risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital.	Approved
Homatropine	The risk or severity of adverse effects can be increased when Homatropine is combined with Pentazocine.	Approved
Hydracarbazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Hydracarbazine.	Experimental
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide.	Approved, Investigational
Hydromorphone	Pentazocine may decrease the analgesic activities of Hydromorphone.	Approved, Illicit
Hydroxyamphetamine	Hydroxyamphetamine may increase the analgesic activities of Pentazocine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pentazocine.	Approved
Ibopamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ibopamine.	Experimental
Iloperidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.	Approved
Indalpine	Pentazocine may increase the serotonergic activities of Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.	Approved
Indiplon	The risk or severity of adverse effects can be increased when Pentazocine is combined with Indiplon.	Investigational
Iofetamine I-123	Iofetamine I-123 may increase the analgesic activities of Pentazocine.	Approved
Ipratropium bromide	The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.	Approved
Iproclozide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Iproclozide.	Withdrawn
Iproniazid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Iproniazid.	Withdrawn
Isocarboxazid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Isoflurane.	Approved, Vet Approved
Isosorbide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Isosorbide.	Approved, Investigational
Ketamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam.	Approved
Ketobemidone	Pentazocine may decrease the analgesic activities of Ketobemidone.	Approved, Investigational
L-Tryptophan	L-Tryptophan may increase the serotonergic activities of Pentazocine.	Approved, Nutraceutical, Withdrawn
Lamotrigine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Lamotrigine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Levobupivacaine.	Approved, Investigational
Levocabastine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Pentazocine is combined with Levodopa.	Approved
Levomethadyl Acetate	Pentazocine may decrease the analgesic activities of Levomethadyl Acetate.	Approved, Investigational
Levomilnacipran	Pentazocine may increase the serotonergic activities of Levomilnacipran.	Approved, Investigational
Levorphanol	Pentazocine may decrease the analgesic activities of Levorphanol.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Lidocaine.	Approved, Vet Approved
Lisdexamfetamine	Lisdexamfetamine may increase the analgesic activities of Pentazocine.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Pentazocine is combined with Lithium.	Approved
Lofentanil	Pentazocine may decrease the analgesic activities of Lofentanil.	Illicit
Loprazolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Loratadine.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Pentazocine.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Lormetazepam.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.	Approved, Investigational
Magnesium sulfate	The therapeutic efficacy of Pentazocine can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Mannitol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.	Approved, Investigational
Mazaticol	The risk or severity of adverse effects can be increased when Mazaticol is combined with Pentazocine.	Experimental
Mebanazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mebanazine.	Withdrawn
Mebicar	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mebicar.	Experimental
Mebutizide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mebutizide.	Experimental
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.	Approved, Investigational
Meclizine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Meclizine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Medetomidine.	Vet Approved
Mefruside	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mefruside.	Experimental
Melatonin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Melperone.	Approved, Investigational
Mephedrone	Mephedrone may increase the analgesic activities of Pentazocine.	Investigational
Mephentermine	Mephentermine may increase the analgesic activities of Pentazocine.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.	Approved, Illicit
Meptazinol	Pentazocine may decrease the analgesic activities of Meptazinol.	Experimental
Mersalyl	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mersalyl.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Mesoridazine.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.	Approved
Methadone	Pentazocine may decrease the analgesic activities of Methadone.	Approved
Methadyl Acetate	Pentazocine may decrease the analgesic activities of Methadyl Acetate.	Approved, Illicit
Methamphetamine	Methamphetamine may increase the analgesic activities of Pentazocine.	Approved, Illicit
Methantheline	The risk or severity of adverse effects can be increased when Methantheline is combined with Pentazocine.	Approved, Investigational
Methapyrilene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methaqualone.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methazolamide.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine.	Approved
Methotrimeprazine	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methoxyflurane.	Approved, Investigational, Vet Approved
Methoxyphenamine	Methoxyphenamine may increase the analgesic activities of Pentazocine.	Experimental
Methscopolamine	The risk or severity of adverse effects can be increased when Methscopolamine is combined with Pentazocine.	Approved
Methsuximide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methyclothiazide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylecgonine.	Experimental
Methylene blue	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylene blue.	Approved, Investigational
Methylnaltrexone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylnaltrexone.	Approved
Methylphenobarbital	The risk or severity of adverse effects can be increased when Pentazocine is combined with Methylphenobarbital.	Approved
Methylscopolamine bromide	The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Pentazocine.	Approved
Meticrane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Meticrane.	Experimental
Metixene	The risk or severity of adverse effects can be increased when Metixene is combined with Pentazocine.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.	Approved
Metyrosine	Pentazocine may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.	Approved, Illicit
Midomafetamine	Midomafetamine may increase the analgesic activities of Pentazocine.	Experimental, Illicit, Investigational
Milnacipran	Pentazocine may increase the serotonergic activities of Milnacipran.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Minaprine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved, Investigational
Mirtazapine	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
MMDA	MMDA may increase the analgesic activities of Pentazocine.	Experimental, Illicit
Moclobemide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Moclobemide.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Molindone.	Approved
Moricizine	Moricizine may increase the hypotensive activities of Pentazocine.	Approved, Investigational, Withdrawn
Morphine	Pentazocine may decrease the analgesic activities of Morphine.	Approved, Investigational
Muzolimine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Muzolimine.	Experimental
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved, Investigational
Nalbuphine	Pentazocine may decrease the analgesic activities of Nalbuphine.	Approved
Naloxegol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Naloxegol.	Approved
Naltrexone	The therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone.	Approved, Investigational, Vet Approved
Nefazodone	Pentazocine may increase the serotonergic activities of Nefazodone.	Approved, Withdrawn
Nialamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Nialamide.	Withdrawn
Nicomorphine	Pentazocine may decrease the analgesic activities of Nicomorphine.	Experimental
Nitrazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrazepam.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Norflurane.	Approved, Investigational
Normethadone	Pentazocine may decrease the analgesic activities of Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Nortriptyline.	Approved
Octamoxin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Octamoxin.	Withdrawn
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ondansetron.	Approved
Opium	Pentazocine may decrease the analgesic activities of Opium.	Approved, Illicit
Orphenadrine	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Pentazocine is combined with Osanetant.	Investigational
Otilonium	The risk or severity of adverse effects can be increased when Otilonium is combined with Pentazocine.	Experimental, Investigational
Oxazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxethazaine.	Approved, Investigational
Oxitropium	The risk or severity of adverse effects can be increased when Oxitropium is combined with Pentazocine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Oxybuprocaine.	Approved, Investigational
Oxybutynin	The risk or severity of adverse effects can be increased when Oxybutynin is combined with Pentazocine.	Approved, Investigational
Oxycodone	Pentazocine may decrease the analgesic activities of Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	Pentazocine may decrease the analgesic activities of Oxymorphone.	Approved, Investigational, Vet Approved
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pentazocine.	Approved
Paliperidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Paliperidone.	Approved
Pamabrom	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pamabrom.	Approved
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.	Approved
Paraldehyde	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Pargyline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pargyline.	Approved
Paroxetine	Pentazocine may increase the serotonergic activities of Paroxetine.	Approved, Investigational
Pegvisomant	The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.	Approved
Penfluridol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Penfluridol.	Experimental
Pentobarbital	The risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine.	Approved, Investigational, Vet Approved
Pentolinium	The risk or severity of adverse effects can be increased when Pentolinium is combined with Pentazocine.	Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved
Perazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Perazine.	Approved, Investigational
Perospirone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Perphenazine.	Approved
Pethidine	Pentazocine may decrease the analgesic activities of Pethidine.	Approved
Phenazocine	Pentazocine may decrease the analgesic activities of Phenazocine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenelzine.	Approved
Phenglutarimide	The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pentazocine.	Experimental
Phenibut	The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenibut.	Experimental
Pheniprazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pheniprazine.	Withdrawn
Phenobarbital	The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenobarbital.	Approved, Investigational
Phenoperidine	Pentazocine may decrease the analgesic activities of Phenoperidine.	Experimental
Phenoxyethanol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxyethanol.	Approved
Phenoxypropazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenoxypropazine.	Withdrawn
Phentermine	Phentermine may increase the analgesic activities of Pentazocine.	Approved, Illicit
Phenytoin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone.	Approved, Investigational
Pipecuronium	The risk or severity of adverse effects can be increased when Pipecuronium is combined with Pentazocine.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pipotiazine.	Approved, Investigational
Pirenzepine	The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.	Approved
Piretanide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.	Approved
Piritramide	Pentazocine may decrease the analgesic activities of Piritramide.	Approved, Investigational
Pirlindole	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pirlindole.	Approved
Pivhydrazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pivhydrazine.	Withdrawn
Pizotifen	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pizotifen.	Approved
Polythiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.	Approved
Potassium	The risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.	Approved, Investigational
Potassium Citrate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.	Approved, Investigational, Vet Approved
Pramipexole	Pentazocine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam.	Approved, Illicit
Pregabalin	The therapeutic efficacy of Pentazocine can be increased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Prilocaine.	Approved
Primidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Procarbazine.	Approved, Investigational
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pentazocine.	Approved, Vet Approved
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Pentazocine.	Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine.	Approved, Vet Approved
Promethazine	Promethazine may increase the hypotensive activities of Pentazocine.	Approved, Investigational
Propanidid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Propanidid.	Experimental
Propantheline	The risk or severity of adverse effects can be increased when Propantheline is combined with Pentazocine.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Proparacaine.	Approved, Vet Approved
Propericiazine	Propericiazine may increase the hypotensive activities of Pentazocine.	Approved, Investigational
Propiopromazine	Propiopromazine may increase the hypotensive activities of Pentazocine.	Vet Approved
Propiverine	The risk or severity of adverse effects can be increased when Propiverine is combined with Pentazocine.	Approved, Investigational
Propofol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Pentazocine is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Pentazocine is combined with PSD502.	Investigational
Pseudoephedrine	Pseudoephedrine may increase the analgesic activities of Pentazocine.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.	Approved
Quinethazone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Quinethazone.	Approved
Quinidine	The risk or severity of adverse effects can be increased when Quinidine is combined with Pentazocine.	Approved, Investigational
Quinisocaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Quinisocaine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon.	Approved, Investigational
Ramosetron	Pentazocine may increase the constipating activities of Ramosetron.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Rasagiline.	Approved
Remifentanil	Pentazocine may decrease the analgesic activities of Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Remoxipride.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Pentazocine.	Approved, Investigational
Rilpivirine	The serum concentration of Pentazocine can be decreased when it is combined with Rilpivirine.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ritanserin.	Investigational
Ritobegron	Ritobegron may increase the analgesic activities of Pentazocine.	Investigational
Rolofylline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Rolofylline.	Investigational
Romifidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Romifidine.	Vet Approved
Ropinirole	Pentazocine may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ropivacaine.	Approved
Rotigotine	Pentazocine may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Pentazocine.	Approved
Safrazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Safrazine.	Withdrawn
Scopolamine	The risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.	Approved, Investigational
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Selegiline.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Pentazocine is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	Pentazocine may increase the serotonergic activities of Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved
Solifenacin	The risk or severity of adverse effects can be increased when Solifenacin is combined with Pentazocine.	Approved
Spiradoline	The risk or severity of adverse effects can be increased when Pentazocine is combined with Spiradoline.	Investigational
Spironolactone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone.	Approved
Stiripentol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Stiripentol.	Approved
Succinylcholine	Succinylcholine may increase the bradycardic activities of Pentazocine.	Approved
Sufentanil	Pentazocine may decrease the analgesic activities of Sufentanil.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Sultopride.	Experimental
Suvorexant	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tasimelteon.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Pentazocine.	Approved, Investigational
Tetrabenazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine.	Approved, Investigational
Tetracaine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracaine.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrodotoxin.	Investigational
Thalidomide	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theobromine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Theobromine.	Approved, Investigational
Thiamylal	The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.	Approved, Vet Approved
Thiazinam	Thiazinam may increase the hypotensive activities of Pentazocine.	Experimental
Thiethylperazine	Thiethylperazine may increase the hypotensive activities of Pentazocine.	Withdrawn
Thiopental	The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiopental.	Approved, Vet Approved
Thioproperazine	Thioproperazine may increase the hypotensive activities of Pentazocine.	Approved
Thioridazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Thioridazine.	Approved, Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiapride.	Approved, Investigational
Ticrynafen	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ticrynafen.	Withdrawn
Tiletamine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tiletamine.	Vet Approved
Tilidine	Pentazocine may decrease the analgesic activities of Tilidine.	Experimental
Tiotropium	The risk or severity of adverse effects can be increased when Tiotropium is combined with Pentazocine.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tizanidine.	Approved, Investigational
Tolcapone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tolcapone.	Approved, Withdrawn
Toloxatone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Toloxatone.	Approved
Tolterodine	The risk or severity of adverse effects can be increased when Tolterodine is combined with Pentazocine.	Approved, Investigational
Tolvaptan	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tolvaptan.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Topiramate.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.	Approved
Tramadol	Pentazocine may decrease the analgesic activities of Tramadol.	Approved, Investigational
Tranylcypromine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone.	Approved, Investigational
Triamterene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Triazolam.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Pentazocine is combined with Tricaine methanesulfonate.	Vet Approved
Trichlormethiazide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.	Approved, Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trichloroethylene.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Triflupromazine.	Approved, Vet Approved
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pentazocine.	Approved
Trimethaphan	The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pentazocine.	Approved, Investigational
Trimipramine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Triprolidine.	Approved
Tropatepine	The risk or severity of adverse effects can be increased when Tropatepine is combined with Pentazocine.	Experimental
Tropicamide	The risk or severity of adverse effects can be increased when Tropicamide is combined with Pentazocine.	Approved, Investigational
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Pentazocine.	Approved
Tubocurarine	The risk or severity of adverse effects can be increased when Tubocurarine is combined with Pentazocine.	Approved
Ularitide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ularitide.	Investigational
Umeclidinium	The risk or severity of adverse effects can be increased when Umeclidinium is combined with Pentazocine.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Pentazocine is combined with Valproic Acid.	Approved, Investigational
Vecuronium	The risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.	Approved
Vemurafenib	The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pentazocine.	Approved
Venlafaxine	Pentazocine may increase the serotonergic activities of Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Pentazocine is combined with Veralipride.	Experimental
Vigabatrin	The risk or severity of adverse effects can be increased when Pentazocine is combined with Vigabatrin.	Approved
Vinyl ether	The risk or severity of adverse effects can be increased when Pentazocine is combined with Vinyl ether.	Experimental
Vortioxetine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Vortioxetine.	Approved, Investigational
Xenon	The risk or severity of adverse effects can be increased when Pentazocine is combined with Xenon.	Experimental
Xipamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Xipamide.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Ziconotide.	Approved
Zimelidine	Pentazocine may increase the serotonergic activities of Zimelidine.	Withdrawn
Ziprasidone	The risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentazocine.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Pentazocine is combined with Zolazepam.	Vet Approved
Zolpidem	Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Pentazocine is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	The risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Take without regard to meals. Avoid alcohol.

References

General References

Not Available

External Links

Human Metabolome Database: HMDB0014790
KEGG Drug: D00498
KEGG Compound: C07421
PubChem Compound: 441278
PubChem Substance: 46506363
ChemSpider: 390041
BindingDB: 50001028
ChEBI: 7982
ChEMBL: CHEMBL560
Therapeutic Targets Database: DAP000356
PharmGKB: PA164744326
IUPHAR: 1606
Guide to Pharmacology: GtP Drug Page
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Pentazocine

ATC Codes

N02AD01 — Pentazocine

AHFS Codes

28:08.12 — Opiate Partial Agonists

MSDS

Download (48.4 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Treatment	Treatment of Menopausal Hot Flashes	1
2	Completed	Treatment	Bipolar Disorder (BD)	1
2	Completed	Treatment	Bipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes / Schizoaffective Disorders	1
4	Unknown Status	Treatment	Anaesthesia therapy / Pregnancy Termination	1
Not Available	Completed	Treatment	Headaches / Migraines	1

Pharmacoeconomics

Manufacturers

Sanofi aventis us llc
Hospira inc

Packagers

A-S Medication Solutions LLC
Dispensing Solutions
Diversified Healthcare Services Inc.
Hospira Inc.
Kaiser Foundation Hospital
Keltman Pharmaceuticals Inc.
Mallinckrodt Inc.
Nucare Pharmaceuticals Inc.
Ohm Laboratories Inc.
PD-Rx Pharmaceuticals Inc.
Pharmedix
Physicians Total Care Inc.
Ranbaxy Laboratories
Rebel Distributors Corp.
Sanofi-Aventis Inc.
Southwood Pharmaceuticals
Stat Rx Usa
Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Tablet	Oral
Injection, solution	Intramuscular; Intravenous; Subcutaneous	30 mg/mL
Solution	Intramuscular; Intravenous; Subcutaneous	30 mg
Tablet	Oral	50 mg
Liquid	Intramuscular; Intravenous; Subcutaneous	30 mg

Prices

Unit description	Cost	Unit
Talwin 30 mg/ml vial	14.78USD	ml
Talwin 30 mg/ml ampul	4.86USD	ml
Talwin 30 mg/ml	1.64USD	ml
Talwin 50 mg Tablet	0.47USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	146.3 °C	PhysProp
logP	4.64	DAYLIGHT (1999)
pKa	8.88	SANGSTER (1994)

Predicted Properties

Property	Value	Source
Water Solubility	0.122 mg/mL	ALOGPS
logP	4.44	ALOGPS
logP	3.89	ChemAxon
logS	-3.4	ALOGPS
pKa (Strongest Acidic)	7.59	ChemAxon
pKa (Strongest Basic)	12.4	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	23.47 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	89.8 m³·mol^-1	ChemAxon
Polarizability	33.86 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9931
Blood Brain Barrier	+	0.9769
Caco-2 permeable	+	0.7902
P-glycoprotein substrate	Substrate	0.9014
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Inhibitor	0.6975
Renal organic cation transporter	Inhibitor	0.6982
CYP450 2C9 substrate	Non-substrate	0.7947
CYP450 2D6 substrate	Substrate	0.8919
CYP450 3A4 substrate	Substrate	0.7819
CYP450 1A2 substrate	Inhibitor	0.5886
CYP450 2C9 inhibitor	Non-inhibitor	0.8321
CYP450 2D6 inhibitor	Inhibitor	0.8147
CYP450 2C19 inhibitor	Non-inhibitor	0.8585
CYP450 3A4 inhibitor	Non-inhibitor	0.8155
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.778
Ames test	Non AMES toxic	0.8231
Carcinogenicity	Non-carcinogens	0.9322
Biodegradation	Not ready biodegradable	0.9888
Rat acute toxicity	2.4411 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Strong inhibitor	0.6301
hERG inhibition (predictor II)	Inhibitor	0.5

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as 2,6-dimethyl-3-benzazocines. These are aromatic compounds containing a 6,7-benzomorphan skeleton, which is substituted by methyl group at the 2- and 6-positions.
Kingdom: Organic compounds
Super Class: Alkaloids and derivatives
Class: 6,7-benzomorphans
Sub Class: 2,6-dimethyl-3-benzazocines
Direct Parent: 2,6-dimethyl-3-benzazocines
Alternative Parents: 4-hydroxy-6,7-benzomorphans / Benzazocines / Tetralins / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compoundsHydrocarbon derivatives
show 1 more
Substituents: 2,6-dimethyl-3-benzazocine / 4-hydroxy-6,7-benzomorphan / Benzazocine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Piperidine / Benzenoid / Tertiary amine / Tertiary aliphatic amine
show 10 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: benzazocine (CHEBI:7982)

Targets

Details1. Mu-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Antagonist

General Function: Voltage-gated calcium channel activity
Specific Function: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name: OPRM1
Uniprot ID: P35372
Uniprot Name: Mu-type opioid receptor
Molecular Weight: 44778.855 Da

References

Levine JD, Gordon NC: Synergism between the analgesic actions of morphine and pentazocine. Pain. 1988 Jun;33(3):369-72. [PubMed:3419842]
Martin BR, Katzen JS, Woods JA, Tripathi HL, Harris LS, May EL: Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain. J Pharmacol Exp Ther. 1984 Dec;231(3):539-44. [PubMed:6094791]
Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Effects of diabetes on the antinociceptive effect of (+/-)pentazocine in mice. Res Commun Chem Pathol Pharmacol. 1994 Apr;84(1):105-10. [PubMed:8042002]
Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334]
Saha N, Datta H, Sharma PL: Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian J Physiol Pharmacol. 1990 Jul;34(3):179-82. [PubMed:2286420]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	2.2	N/A	N/A	9686407

Details2. Kappa-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Opioid receptor activity
Specific Function: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name: OPRK1
Uniprot ID: P41145
Uniprot Name: Kappa-type opioid receptor
Molecular Weight: 42644.665 Da

References

Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	3.1	N/A	N/A	8360875
Ki (nM)	3.8	N/A	N/A	8098066

Details3. Sigma non-opioid intracellular receptor 1

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Opioid receptor activity
Specific Function: Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma m...
Gene Name: SIGMAR1
Uniprot ID: Q99720
Uniprot Name: Sigma non-opioid intracellular receptor 1
Molecular Weight: 25127.52 Da

References

Chien CC, Pasternak GW: (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol. 1995 Dec 27;294(1):303-8. [PubMed:8788445]
Colabufo NA, Contino M, Inglese C, Niso M, Perrone R, Roperto S, Roperto F: In vitro and ex vivo characterization of sigma-1 and sigma-2 receptors: agonists and antagonists in biological assays. Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):161-71. [PubMed:20021350]
Dun Y, Thangaraju M, Prasad P, Ganapathy V, Smith SB: Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94. [PubMed:17898305]
Mamolo MG, Zampieri D, Zanette C, Florio C, Collina S, Urbano M, Azzolina O, Vio L: Substituted benzylaminoalkylindoles with preference for the sigma2 binding site. Eur J Med Chem. 2008 Oct;43(10):2073-81. Epub 2007 Sep 26. [PubMed:18069094]
Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, Mavlyutov T, Ruoho AE: Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol. 2007 Oct;72(4):921-33. Epub 2007 Jul 10. [PubMed:17622576]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:02

Pentazocine

Identification

Structure for DB00652 (Pentazocine)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References